EUVIMEDEUVIMED entdecken
Crossref

Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo

Elda Gonçalves-Santos, Ivo S Caldas, Valquiria  Fernandes, Lucas L Franco, Mônica F Pelozo, Fernando Feltrim, Juliana S Maciel, Jose Vaz C Machado, Reggiani V Gonçalves, Rômulo D Novaes

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Elda Gonçalves-Santos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Chagas Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: From well-delimited immunomodulatory, redox and antimicrobial properties; metronidazole and eugenol were used as structural platforms to assembly two new molecular hybrids (AD06 and AD07), whose therapeutic relevance was analyzed on T. cruzi infection in vitro and in vivo. METHODS: Non-infected, T. cruzi-infected H9c2 cardiomyocytes, and mice non-treated and treated with vehicle, benznidazole (Bz - reference drug), AD06 and AD07 were investigated. Parasitological, prooxidant, antioxidant, microstructural, immunological, and hepatic function markers were analyzed. RESULTS: Our findings indicated that in addition to having a direct antiparasitic effect on T. cruzi, metronidazole/eugenol hybrids (especially AD07) attenuated cellular parasitism, reactive species biosynthesis and oxidative stress in infected cardiomyocytes in vitro. Although AD06 and AD07 exerted no relevant impact on antioxidant enzymes activity (CAT, SOD, GR and GPx) in host cells, these drugs (especially AD07) attenuated trypanothione reductase activity in T. cruzi, which increased parasite's susceptibility to in vitro pro-oxidant challenge. AD06 and AD07 were well tolerated and do not determine humoral response suppression, mortality (100 % survival) or hepatotoxicity in mice, as indicated by transaminases plasma levels. AD07 also induced relevant in vivo antiparasitic and cardioprotective effects, attenuating parasitemia, cardiac parasite load and myocarditis in T. cruzi-infected mice. Although this cardioprotective response is potentially related to AD07 antiparasitic effect, a direct anti-inflammatory potential of this molecular hybrid cannot be ruled out. CONCLUSION: Taken together, our findings indicated that the new molecular hybrid AD07 stood out as a potentially relevant candidate for the development of new, safe and more effective drug regimens for T. cruzi infection treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma cruziChagas DiseaseMiceAnimalsMetronidazoleEugenolAntioxidantsMyocytes, CardiacAntiparasitic Agents

Stichwörter der Autor:innen

Antiparasitic chemotherapyChagas diseaseExperimental parasitologyInfectious myocarditis

Substanzen

MetronidazoleEugenolAntioxidantsAntiparasitic Agents

Autor:innen und Institutionen

  • Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil.
  • Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil; Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Ger…
  • Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil.
  • Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil; Faculdade de Ciências Farmacêuticas, Departamento de Alimentos e Medicamentos, Universidade…
  • Departamento de Biologia Animal, Programa de Pós-Graduação em Biologia Animal, Universidade Federal de Viçosa, Viçosa 36570-900, Minas Gerais, Brazil.
  • Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-001, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Al…

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Gonçalves-Santos, E., Caldas, I. S., Fernandes, V. Â., Franco, L. L., Pelozo, M. F., Feltrim, F., Maciel, J. S., Machado, J. V. C., Gonçalves, R. V., & Novaes, R. D. (2023). Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110416

Vancouver

Gonçalves-Santos E, Caldas IS, Fernandes VÂ, Franco LL, Pelozo MF, Feltrim F, et al. Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110416

BibTeX
@article{GonalvesSantos2023,
  author = {Gonçalves-Santos, Elda and Caldas, Ivo S and Fernandes, Valquiria  and Franco, Lucas L and Pelozo, Mônica F and Feltrim, Fernando and Maciel, Juliana S and Machado, Jose Vaz C and Gonçalves, Reggiani V and Novaes, Rômulo D},
  title = {Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110416}
}
Kostenlos starten →